PR99082

TAMPA, Fla., Dec. 2, 2022 /PRNewswire=KYODO JBN/ --

    VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus

Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept

Medical Inc. [https://www.conceptmedical.com/] hosted a lunch symposium titled

'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which

explored the utility of Sirolimus Coated Balloon treatment in PAD. The session

was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof.

Aloke Finn with interesting presentations by Prof. Ulf Teichgräber and Prof.

Francesco Liistro.

    One of the highlights of the session was the follow up data of clinical

outcomes of the XTOSI Trial.  XTOSI (Xtreme Touch Sirolimus coated PTA balloon)

is a single arm trial for Sirolimus Coated Balloon (MagicTouch PTA)

[https://www.conceptmedical.com/product/magic-touch-pta/] investigating the

clinical use and safety of the device in the treatment of infrainguinal

Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized,

all comers single-arm study, led by PI Prof. Edward Choke enrolled 50 patients

to study the Magic Touch PTA

[https://www.conceptmedical.com/product/magic-touch-pta/] Sirolimus Coated

Balloon (Concept Medical Inc.) [https://www.conceptmedical.com/] at Sengkang

General Hospital, Singapore. It is the world's first trial of Sirolimus Coated

Balloon for BTK disease and has the longest follow up data. While the primary

endpoints already suggested promising patency and safety at 6 months, the data

presented at VEITH 2022 shed more light on the longer-term efficacy and the

safety of the Sirolimus Coated Balloon.

    Prof. Edward Choke, further presented updates on the FUTURE SFA and FUTURE

BTK RCTs, a family of randomised trials set to enrol 279 and 219 patients

respectively, against standard uncoated balloon in 2:1 fashion and are ongoing

in Singapore, Taiwan and Thailand. FUTURE BTK has already completed 25% of its

enrolment target, credits to the principal investigators of all sites involved.

    Sirolimus Coated Balloon for PAD continues its march, knocking on the doors

of the US and lighting up the iconic New York Times Square with a dazzling

display of the study results of XTOSI and the recruitment status of the FUTURE

BTK.

    Watch the complete session to know more about exciting clinical data:

https://youtu.be/2xokmMuhzuc

    Logo: https://mma.prnewswire.com/media/1926812/Concept_Medical_Logo.jpg

    Photo:

https://mma.prnewswire.com/media/1960489/Edward_Choke_MagicTouch_XTOSI.jpg

    Source: Concept Medical Inc.